fbpx
December 8, 2022

Do Buddhist Teachings Protect Against Depression? Do Buddhist Teachings Protect Against Depression?

Following five key Buddhist teachings may help protect against depression, new research shows. A study from Thailand showed that among people who observed what are known […]
December 7, 2022

States’ Push to Legalize Psychedelics Gaining Momentum States’ Push to Legalize Psychedelics Gaining Momentum

The push to legalize psychedelic drugs is gaining momentum in states across the country, with a sevenfold increase in the number of decriminalization bills since 2019, […]
December 6, 2022

Aerobic Exercise Augments PTSD Therapy Aerobic Exercise Augments PTSD Therapy

A brief aerobic exercise intervention can augment the benefits of exposure therapy for posttraumatic stress disorder (PTSD), new research suggests. Investigators randomly assigned individuals with PTSD […]
December 5, 2022

Antipsychotic Shows Benefit for Alzheimer’s Agitation Antipsychotic Shows Benefit for Alzheimer’s Agitation

SAN FRANCISCO — In a widely anticipated report, researchers reported that a phase 3 study showed statistically significant improvements in patients with agitation related to Alzheimer’s […]
December 5, 2022

Personalized Approach to Alzheimer’s Risk Factors Boosts Cognition Personalized Approach to Alzheimer’s Risk Factors Boosts Cognition

SAN FRANCISCO — A multidomain intervention that includes counseling by health coaches is associated with “modest” improvements in cognition in older adults who have at least […]
December 2, 2022

Confirmed: Amyloid, Tau Rise Years Before Alzheimer’s Onset Confirmed: Amyloid, Tau Rise Years Before Alzheimer’s Onset

A new study supports the hypothesis that changes in levels of amyloid and tau occur many years before the emergence of clinical symptoms of Alzheimer’s disease […]
December 2, 2022

Higher Potency of Fentanyl Affects Addiction Treatment, Screening Higher Potency of Fentanyl Affects Addiction Treatment, Screening

As fentanyl-related overdose deaths continue to increase, clinicians should take note of important differences that set the drug apart from the other drugs of misuse — […]
December 1, 2022

Odd Twist in Phase 3 Alzheimer’s Trial for Novel Tau Inhibitor Odd Twist in Phase 3 Alzheimer’s Trial for Novel Tau Inhibitor

SAN FRANCISCO ― A drug designed to harness tau tangles produced in Alzheimer’s disease (AD) failed to reach its primary endpoints of change in cognition and […]
November 30, 2022

‘Modest’ Benefit for Lecanemab in AD, Adverse Events Common ‘Modest’ Benefit for Lecanemab in AD, Adverse Events Common

SAN FRANCISCO — Widely anticipated data from a phase 3 trial of the monoclonal antibody lecanemab suggest the drug “modestly” relieved cognitive impairment in patients with […]
google.com, pub-5711488453051849, DIRECT, f08c47fec0942fa0